Compare Bill.com Holdings Inc (BILL) vs GSK plc (GSK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bill.com Holdings Inc vs GSK plc — how do they compare? Bill.com Holdings Inc trades at $48.45 (market cap $4.93B), while GSK plc trades at $50.29 (market cap $102.60B). The key difference: GSK plc is far larger — about 20.8× Bill.com Holdings Inc's market cap, and GSK plc pays a 3.57% dividend while Bill.com Holdings Inc pays none. Which is the better fit depends on your goals.
| BILL | GSK | |
|---|---|---|
Market Cap | $4.93B | $102.60B |
Sector | Technology | Health |
52-Week High | $56.32 | $61.18 |
52-Week Low | $31.96 | $38.22 |
Enterprise Value | $4.64B | $123.04B |
Dividend Yield | — | 3.57% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BILL Holdings trades at $48.37, down 1.81% today, with a bullish technical signal and strong analyst support (56% buy ratings). The company shows improving fundamentals with revenue growth to $1.46B in 2025 and three consecutive quarterly EPS beats, though profitability remains thin with a net margin of 0.01%. Recent news highlights AI-driven strategy and operational efficiency gains.
Outlook is cautiously optimistic given earnings momentum and institutional accumulation, but high valuation (P/E 213.91) and negative cash flow from investing pose risks. Upside to consensus price target $45.67 appears limited at current levels, requiring sustained execution for further gains.
GSK trades at $50.27, down 3.62% today, with a bearish technical signal but strong fundamentals including a P/E of 16.02 and net income margin of 14.52%. Recent quarters show earnings beats, and the company announced a $2.52 billion cost-saving plan to boost its drug pipeline. Cash flow from operations remains robust at $7.74 billion for 2025.
The outlook is mixed: analyst consensus leans hold (55.18%) amid valuation concerns, but revenue growth and pipeline investments support long-term potential. Key risks include competitive pressures and regulatory uncertainty, as highlighted by recent news on vaccine policies. The stock offers a dividend yield with payments scheduled through 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bill.com Holdings Inc
Bill.com Holdings Inc is a provider of cloud-based software that simplifies, digitizes, and automates financial operations for SMBs. Its artificial-intelligence enabled financial software platform used mostly to build connections between customers, suppliers, and clients. The company's platform generates and process invoices, streamline approvals, send and receive payments, sync with their accounting system, and manage their cash. The firm generates revenue through subscription and transaction fees.
Read more on BILL →About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →
